DrugPatentWatch Database Preview
Drugs in Development Information for DEBIO-1347
Development status for investigational drug DEBIO-1347: Sponsors, patents, clinical trial progress
DEBIO-1347 is an investigational drug.
There have been 20 clinical trials for DEBIO-1347.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2007.
The most common disease conditions in clinical trials are Bacterial Infections, Carcinoma, Non-Small-Cell Lung, and Communicable Diseases. The leading clinical trial sponsors are Debiopharm International SA, Centre Leon Berard, and Merck Sharp & Dohme Corp.
Summary for DEBIO-1347
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2007-09-01) |
| Vendors | 35 |
Recent Clinical Trials for DEBIO-1347
| Title | Sponsor | Phase |
|---|---|---|
| Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | Debiopharm International SA | Phase 1 |
| Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | Debiopharm International SA | Phase 1/Phase 2 |
| Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma | Debiopharm International SA | Phase 1 |
Clinical Trial Summary for DEBIO-1347
Top disease conditions for DEBIO-1347
Top clinical trial sponsors for DEBIO-1347
US Patents for DEBIO-1347
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
